{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:53:51Z","timestamp":1790812431730,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T00:00:00Z","timestamp":1494806400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Novartis de Colombia","award":["0035-2015"],"award-info":[{"award-number":["0035-2015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s11096-017-0484-9","type":"journal-article","created":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T08:51:01Z","timestamp":1494838261000},"page":"851-859","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Use patterns of first-line inhibitors of tyrosine kinase and time to change to second-line therapy in chronic myeloid leukemia"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8455-0936","authenticated-orcid":false,"given":"Jorge Enrique","family":"Machado-Alba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Enrique","family":"Machado-Duque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,15]]},"reference":[{"key":"484_CR1","unstructured":"Instituto Nacional de Cancerolog\u00eda - ESE. INC. Colombia. C\u00e1ncer en cifras, Incidencias por tipo de c\u00e1ncer 2002\u20132006 (internet). http:\/\/www.cancer.gov.co\/cancer_en_cifras . Cited 21 Feb 2017."},{"issue":"9584","key":"484_CR2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann R, Hochhaus A, Baccarani M. European Leukemia Net: chronic myeloid leukaemia. Lancet. 2007;370(9584):342\u201350.","journal-title":"Lancet"},{"key":"484_CR3","first-page":"905","volume-title":"Harrison\u2019s principles of internal medicine","author":"M Wetzler","year":"2011","unstructured":"Wetzler M, Marcucci G, Bloomfield CD. Acute and Chronic Myeloid Leukemia. Chapter 109. In: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J, editors. Harrison\u2019s principles of internal medicine. 18th ed. New York: McGraw-Hill, Medical Pub. Division; 2011. p. 905\u201318.","edition":"18"},{"issue":"9976","key":"484_CR4","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","volume":"385","author":"JF Apperley","year":"2015","unstructured":"Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385(9976):1447\u201359.","journal-title":"Lancet"},{"issue":"14","key":"484_CR5","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031\u20137.","journal-title":"N Engl J Med"},{"issue":"23","key":"484_CR6","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408\u201317.","journal-title":"N Engl J Med"},{"issue":"3","key":"484_CR7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1056\/NEJMct071828","volume":"357","author":"CA Schiffer","year":"2007","unstructured":"Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med. 2007;357(3):258\u201365.","journal-title":"N Engl J Med"},{"key":"484_CR8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","volume":"11","author":"S Balabanov","year":"2014","unstructured":"Balabanov S, Braig M, Br\u00fcmmendorf TH. Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia. Drug Discov Today Technol. 2014;11:89\u201399.","journal-title":"Drug Discov Today Technol"},{"issue":"8","key":"484_CR9","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.6004\/jnccn.2014.0108","volume":"12","author":"DD Stenehjem","year":"2014","unstructured":"Stenehjem DD, Albright F, Kuo KL, Raimundo K, Bauer H, Shami PJ, et al. Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database. J Natl Compr Cancer Netw. 2014;12(8):1113\u201321.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"5","key":"484_CR10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","volume":"7","author":"E Weisberg","year":"2007","unstructured":"Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007;7(5):345\u201356.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"484_CR11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1470-2045(12)70008-6","volume":"13","author":"S Goulden","year":"2012","unstructured":"Goulden S, Sutcliffe F, Stevens A. NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib. Lancet Oncol. 2012;13(2):127\u20138.","journal-title":"Lancet Oncol"},{"issue":"1","key":"484_CR12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.7705\/biomedica.v34i1.1446","volume":"34","author":"M Romero","year":"2014","unstructured":"Romero M, Ch\u00e1vez D, De Los R\u00edos M, Alvis-Guzm\u00e1n N. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012. Biomedica. 2014;34(1):48\u201359.","journal-title":"Biomedica"},{"issue":"4","key":"484_CR13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.25100\/cm.v43i4.835","volume":"43","author":"G Guevara","year":"2012","unstructured":"Guevara G, Gonz\u00e1lez JA, Lopera DE, Gonz\u00e1lez M, Saavedra JD, Lobaton JF, et al. Follow-up of the tumor load in patients with de novo chronic myeloid leukemia and in complete cytogenetic remission treated with imatinib in Colombia. Colomb Med (Cali). 2012;43(4):267\u201372.","journal-title":"Colomb Med (Cali)"},{"issue":"5","key":"484_CR14","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clml.2013.03.018","volume":"13","author":"EJ Jabbour","year":"2013","unstructured":"Jabbour EJ, Cortes JE, Kantarjian HM. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk. 2013;13(5):515\u201329.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"484_CR15","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","volume":"113","author":"E Jabbour","year":"2009","unstructured":"Jabbour E, Kantarjian HM, Jones D, Shan J, O\u2019Brien S, Reddy N, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood. 2009;113:2154\u201360.","journal-title":"Blood"},{"issue":"1","key":"484_CR16","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.clinthera.2014.10.019","volume":"37","author":"HJ Henk","year":"2015","unstructured":"Henk HJ, Woloj M, Shapiro M, Whiteley J. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States. Clin Ther. 2015;37(1):124\u201333.","journal-title":"Clin Ther"},{"issue":"3","key":"484_CR17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12185-012-1010-4","volume":"95","author":"D Mitra","year":"2012","unstructured":"Mitra D, Trask PC, Iyer S, Candrilli SD, Kaye JA. Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study. Int J Hematol. 2012;95(3):263\u201373.","journal-title":"Int J Hematol"},{"issue":"2","key":"484_CR18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1185\/03007995.2014.991817","volume":"31","author":"J Whiteley","year":"2015","unstructured":"Whiteley J, Iyer S, Candrilli SD, Kaye JA. Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea. Curr Med Res Opin. 2015;31(2):299\u2013314.","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"484_CR19","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1185\/03007995.2012.741577","volume":"28","author":"L Chen","year":"2012","unstructured":"Chen L, Gu\u00e9rin A, Xie J, Wu EQ, Yu AP, Ericson SG, et al. Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis. Curr Med Res Opin. 2012;28(11):1831\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"484_CR20","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1185\/03007995.2013.858621","volume":"30","author":"MN Saleh","year":"2014","unstructured":"Saleh MN, Haislip S, Sharpe J, Hess T, Gilmore J, Jackson J, et al. Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting. Curr Med Res Opin. 2014;30(4):529\u201336.","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"484_CR21","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1089\/thy.2010.0251","volume":"20","author":"TD Kim","year":"2010","unstructured":"Kim TD, Schwarz M, Nogai H, Grille P, Westermann J, Pl\u00f6ckinger U. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid. 2010;20(11):1209\u201314.","journal-title":"Thyroid"},{"issue":"3","key":"484_CR22","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s12185-011-0790-2","volume":"93","author":"T Yoshizato","year":"2011","unstructured":"Yoshizato T, Nannya Y, Yoshiki Y, Nakamura F, Imai Y, Ichikawa M, et al. Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia. Int J Hematol. 2011;93(3):400\u20132.","journal-title":"Int J Hematol"},{"issue":"2","key":"484_CR23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jnci.2015.03.004","volume":"27","author":"WA Edesa","year":"2015","unstructured":"Edesa WA, Abdel-malek RR. Impact of imatinib interruption and duration of prior hydroxyurea on the treatment outcome in patients with chronic myeloid leukemia: single institution experience. J Egypt Natl Canc Inst. 2015;27(2):69\u201375.","journal-title":"J Egypt Natl Canc Inst"},{"issue":"17","key":"484_CR24","doi-asserted-by":"crossref","first-page":"7555","DOI":"10.7314\/APJCP.2015.16.17.7555","volume":"16","author":"M Payandeh","year":"2015","unstructured":"Payandeh M, Sadeghi M, Sadeghi E. Treatment and survival in patients with chronic myeloid leukemia in a chronic phase in West Iran. Asian Pac J Cancer Prev. 2015;16(17):7555\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"484_CR25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1756-8722-6-70","volume":"6","author":"D Pulte","year":"2013","unstructured":"Pulte D, Barnes B, Jansen L, Eisemann N, Emrich K, Gondos A, GEKID Cancer Survival Working Group, et al. Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century. J Hematol Oncol. 2013;6(1):70.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"484_CR26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5581\/1516-8484.20140014","volume":"36","author":"MH Almeida de","year":"2014","unstructured":"de Almeida MH, Fogliatto L, Couto D. Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia. Rev Bras Hematol Hemoter. 2014;36(1):54\u20139.","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"6","key":"484_CR27","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/bjc.2012.348","volume":"107","author":"F Efficace","year":"2012","unstructured":"Efficace F, Baccarani M, Rosti G, Cottone F, Castagnetti F, Breccia M, et al. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer. 2012;107(6):904\u20139.","journal-title":"Br J Cancer"},{"issue":"22","key":"484_CR28","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"L Noens","year":"2009","unstructured":"Noens L, van Lierde MA, De Bock R, Verhoef G, Zach\u00e9e P, Berneman Z, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113(22):5401\u201311.","journal-title":"Blood"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-017-0484-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-017-0484-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-017-0484-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T18:39:45Z","timestamp":1602095985000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-017-0484-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,15]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["484"],"URL":"https:\/\/doi.org\/10.1007\/s11096-017-0484-9","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,15]]}}}